Condition: Chikungunya Virus Infection · Sponsor: Centre Hospitalier Universitaire de la Réunion
Against the backdrop of a growing chikungunya epidemic in La Réunion, this prospective study will assess the real-life efficacy, safety and immunogenicity of IXCHIQ® vaccine in vulnerable individuals (seniors, comorbid patients), defined by the French Health Autority (HAS) as at risk of severe or complicated forms and/or chronic disabling forms (chronic arthritis, chronic fatigue phenotypes). This study will also provide input for the preparation of a cluster randomized trial on a population scale.
This description comes directly from the study's public registry record.
Patrick GERARDIN, MD · (262) 2 62 35 9435 · patrick.gerardin@chu-reunion.fr
Florence LEFEBVRE D'HELLENCOURT · +262 262 75 34 71 · promotion.drci@chu-reunion.fr
Always discuss trial participation with your own doctor first.
| CHU La Réunion | Saint-Denis, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06928753